P
US8084042B2ExpiredUtilityPatentIndex 52

Compounds and methods for immunotherapy and diagnosis of tuberculosis

Assignee: REED STEVEN GPriority: Sep 1, 1995Filed: May 7, 2007Granted: Dec 27, 2011
Est. expirySep 1, 2015(expired)· nominal 20-yr term from priority
Inventors:REED STEVEN GSKEIKY YASIR A WDILLON DAVIN CCAMPOS-NETO ANTONIOHOUGHTON RAYMONDVEDVICK THOMAS STWARDZIK DANIEL RLODES MICHAEL JHENDRICKSON RONALD C
A61P 31/04A61P 37/04A61P 31/06C07K 14/35C07K 2319/00A61K 38/00A61K 2039/51A61P 43/00A61K 39/00
52
PatentIndex Score
0
Cited by
353
References
35
Claims

Abstract

Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.

Claims

exact text as granted — not AI-modified
1. A polypeptide comprising (1) a soluble  M. tuberculosis  antigen having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:88 or (2) an immunogenic portion of the amino acid sequence of SEQ ID NO:88. 
     
     
       2. The polypeptide of  claim 1 , comprising an immunogenic portion of the amino acid sequence of SEQ ID NO:88. 
     
     
       3. The polypeptide of  claim 1 , comprising the amino acid sequence of SEQ ID NO:88. 
     
     
       4. The polypeptide of  claim 2 , consisting of an immunogenic portion of the amino acid sequence of SEQ ID NO:88. 
     
     
       5. The polypeptide of  claim 3 , consisting of the amino acid sequence of SEQ ID NO:88. 
     
     
       6. A fusion protein comprising the polypeptide of  claim 1  and a second  M. tuberculosis  antigen. 
     
     
       7. A pharmaceutical composition comprising the fusion protein of  claim 6  and a physiologically acceptable carrier. 
     
     
       8. A vaccine comprising the polypeptide of  claim 1  and a non-specific immune response enhancer. 
     
     
       9. A vaccine comprising the fusion protein of  claim 6  and a non-specific immune response enhancer. 
     
     
       10. The vaccine of  claim 8  or  9 , wherein the non-specific immune response enhancer is an adjuvant. 
     
     
       11. A diagnostic kit comprising:
 (a) the polypeptide of  claim 1 ; and 
 (b) an apparatus sufficient to contact the polypeptide with the dermal cells of a patient. 
 
     
     
       12. The polypeptide of  claim 1 , comprising the amino acid sequence of residues 5-28 of SEQ ID NO:93. 
     
     
       13. The polypeptide of  claim 1 , comprising the amino acid sequence of SEQ ID NO:94. 
     
     
       14. The polypeptide of  claim 1 , comprising the amino acid sequence of residues 4-27 of SEQ ID NO:95. 
     
     
       15. The polypeptide of  claim 1 , comprising the amino acid sequence of residues 4-27 of SEQ ID NO:96. 
     
     
       16. The polypeptide of  claim 1 , comprising the amino acid sequence of residues 4-27 of SEQ ID NO:97. 
     
     
       17. The polypeptide of  claim 1 , comprising the amino acid sequence of residues 4-28 of SEQ ID NO:98. 
     
     
       18. The polypeptide of  claim 1 , consisting of the amino acid sequence of residues 5-28 of SEQ ID NO:93. 
     
     
       19. The polypeptide of  claim 1 , consisting of the amino acid sequence of residues 4-27 of SEQ ID NO:95. 
     
     
       20. The polypeptide of  claim 1 , consisting of the amino acid sequence of residues 4-27 of SEQ ID NO:96. 
     
     
       21. The polypeptide of  claim 1 , consisting of the amino acid sequence of residues 4-27 of SEQ ID NO:97. 
     
     
       22. The polypeptide of  claim 1 , consisting of the amino acid sequence of residues 4-28 of SEQ ID NO:98. 
     
     
       23. A pharmaceutical composition comprising the polypeptide of  claim 1 , wherein the polypeptide comprises the amino acid sequence of residues 5-28 of SEQ ID NO:93, SEQ ID NO:94, residues 4-27 of SEQ ID NO:95, residues 4-27 or SEQ ID NO:96, residues 4-27 of SEQ ID NO:97, or residues 4-28 of SEQ ID NO:98. 
     
     
       24. A pharmaceutical composition comprising the polypeptide of  claim 1 , wherein the polypeptide consists of the amino acid sequence of residues 5-28 of SEQ ID NO:93, SEQ ID NO:94, residues 4-27 of SEQ ID NO:95, residues 4-27 or SEQ ID NO:96, residues 4-27 of SEQ ID NO:97, or residues 4-28 of SEQ ID NO:98. 
     
     
       25. A composition comprising the polypeptide of  claim 1  and a physiologically acceptable carrier. 
     
     
       26. The composition of  claim 2 , wherein the polypeptide comprises and immunogenic portion of the amino acid sequence of SEQ ID NO:88. 
     
     
       27. The composition of  claim 2 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:88. 
     
     
       28. The composition of  claim 2 , wherein the polypeptide consists of immunogenic portion of the amino acid sequence of SEQ ID NO:88. 
     
     
       29. The composition of  claim 2 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:88. 
     
     
       30. The composition of  claim 2 , wherein the polypeptide comprises the amino acid sequence of residues 5-28 of SEQ ID NO:93, SEQ ID NO:94, residues 4-27 of SEQ ID NO:95, residues 4-27 of SEQ ID NO:96, residues 4-27 of SEQ ID NO:97, or residues 4-28 of SEQ ID NO:98. 
     
     
       31. The composition of  claim 25 , wherein the polypeptide consists of the amino acid sequence of residues 5-28 of SEQ ID NO:93, SEQ ID NO:94, residues 4-27 of SEQ ID NO:95, residues 4-27 of SEQ ID NO:96, residues 4-27 of SEQ ID NO:97, or residues 4-28 of SEQ ID NO:98. 
     
     
       32. The polypeptide of  claim 1 , comprising the amino acid sequence of SEQ ID NO:115. 
     
     
       33. The polypeptide of  claim 1 , consisting of the amino acid sequence of SEQ ID NO:115. 
     
     
       34. The composition of  claim 25 , wherein the polypeptide comprises an  M. tuberculosis  antigen having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:88. 
     
     
       35. The composition of  claim 25 , wherein the polypeptide consists of an  M. tuberculosis  antigen having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:88.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.